Navigation Links
Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
Date:12/7/2007

ization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. will co-promote VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide. To access the full U.S. prescribing information for VELCADE, go to: http://www.mlnm.com/products/velcade/full_prescrib_velcade.pdf.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients rec
'/>"/>

SOURCE Ortho Biotech
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Ardelyx, Inc. (NASDAQ: ARDX ... gastrointestinal, and metabolic diseases, today announced that a ... Stage 3 chronic kidney disease patients with type ... the primary endpoint of decreasing the urinary albumin-creatinine ... placebo. Ardelyx formed a partnership ...
(Date:5/5/2015)... , May 5, 2015 /CNW Telbec/ - ... Laval and known under the « ... the closing of the transaction previously announced on April ... issued and outstanding  shares of Orthoconcept (2008) inc.   ... 500 000 common shares (TSXV: ERG) to the vending ...
(Date:5/5/2015)... -- The preclinical contract research organization Absorption Systems , ... safety testing of medical devices, announces that Dr. ... at this week,s annual meeting of The Association for ... Denver, CO. The title of Dr. Gum,s ... Bio-Absorbable Carboxymethyl Hyaluronic Acid (CMHA) Polymer in a Rabbit ...
Breaking Medicine Technology:Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3
... The U.S. Food and Drug Administration today approved Kalydeco ... fibrosis (CF) in patients ages 6 years and older who ... Regulator (CFTR) gene. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... lungs and other organs that ultimately leads to an early ...
... (OTCBB: VYST), the exclusive creator of Vytex® Natural Rubber ... first Chinese patent for its all-natural raw material. The company ... US and abroad that relate to Vytex NRL, with more ... ) The new US patent expands the claims ...
Cached Medicine Technology:FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis 2FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis 3Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex 2Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex 3
(Date:5/5/2015)... 05, 2015 “Given that Hispanics are one ... the CDC report are a major step in the arsenal ... everyone. For the past 30 years, data have accumulated that ... Today we see the urgency and the need to create ... health outcomes for all,” said Jane L. Delgado, PhD, MS, ...
(Date:5/5/2015)... 2015 The global lab automation market ... $3,474.2 Million in 2014, at an estimated CAGR of ... lab automation market on the basis of equipment and ... On the basis of application, Lab Automation Market is ... proteomics solutions. Drug discovery is a major application of ...
(Date:5/5/2015)... The newly minted Regan Arts has just released a unique self-help ... from his 20 years working in the field of wilderness therapy. ... a parenting book and why this one, she replied, “What resonates ... it is a journey, not a destination...that the question is not ... together and sometimes not...that each of our struggles is unique. What ...
(Date:5/5/2015)... Georgia (PRWEB) May 05, 2015 ... of Victoria BC announced the Skedans Sensor Collaboration ... platform, for mobile and web app developers, provides tooling ... airborne and mobile sensors. , The Skedans Sensor Collaboration ... the intersection of the Internet of Things, Web Real ...
(Date:5/5/2015)... Information Innovators Inc. ... federal government, today announced its acquisition of ... solutions exclusively to federal government customers through its ... security, health services, and program management support. The ... as a Third Party Assessment Organization (3PAO) for ...
Breaking Medicine News(10 mins):Health News:“Its about time,” Declares the National Alliance for Hispanic Health on First CDC Study of Hispanic Health 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4
... make you less upset about making errors, according to ... a journal of the Association for Psychological Science. The ... distress-response while participants made mistakes on a test. Those ... less prominent response to mistakes than those who hadn,t. ...
... them to investigate, for the first time, how human testes ... Until now it has been impossible to study testicular development ... to understand the processes that can lead to the onset ... and how factors, such as common environmental chemicals, might play ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... As of 2009, almost 3 in every 10 adults ... in 2007, according to a new government report released Tuesday. ... Disease Control and Prevention (CDC), also found that between 2007-2009, ...
... Project, joined by major consumer, physician and chemical manufacturer ... would give the U.S. Food and Drug Administration (FDA) ... organizations made the announcement in a joint letter to ... Michael Bennet (D-CO), who will introduce this drug safety ...
... all-over tan may be impossible to achieve because some body ... study has found. Researchers - funded by the Medical ... the results explain why some holidaymakers find it so hard ... The findings, published in the journal Experimental Dermatology , ...
... big impact on the food you eat, the clothes you ... in a special section on Culture and Psychology in ... for Psychological Science, psychological scientists Denise C. Park from the ... University of Illinois at Urbana-Champaign discuss ways in which brain ...
Cached Medicine News:Health News:Brain study shows that thinking about God reduces distress -- but only for believers 2Health News:Scientists develop the first model for investigating the origins of testicular cancer in humans 2Health News:Number of Obese Adults Keeps Rising, CDC Says 2Health News:Number of Obese Adults Keeps Rising, CDC Says 3Health News:Consumer and manufacturing groups back bill to protect US drug supply 2Health News:Consumer and manufacturing groups back bill to protect US drug supply 3Health News:All-over tan is a myth, study finds 2Health News:Culture wires the brain: A cognitive neuroscience perspective 2
Superior Skin Care...FlexWear skin barrier provides skin protection for an extended wear time....
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Convenient: accommodates stomas up to 102 mm; wide bottom opening permits hand access; attached pouch closure....
FlexWear is a cross-linked hydrocolloid skin barrier that provides aggressive adherence and is designed for more than one day weartime....
Inquire...
Medicine Products: